The final analysis of the Phase III ALEX trial confirms alectinib's superior long-term efficacy over crizotinib, achieving a median overall survival of 81.1 months and significant intracranial benefits, solidifying its role as the first-line standard of care for ALK-positive advanced non-small cell lung cancer.